CSIMarket
 


United Therapeutics Corporation  (UTHR)
Other Ticker:  
 

Cumulative United Therapeutics's Long Term Debt to Equity for Trailing Twelve Months Period

UTHR's Long Term Debt to Equity for Trailing Twelve Months Period and Long Term Debt, Equity growth


Select the Comparisons : Select the Ratio:

UTHR Long Term Debt to Equity for Trailing Twelve Months Period

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity Growth 24.77 % 25.2 % 25.3 % 22.67 % 21.16 %
Y / Y Long Term Debt Growth -62.5 % -37.5 % 0 % 0 % 0 %
Long Term Debt to Equity for Trailing Twelve Months Period 0.11 0.14 0.16 0.17 0.18
Total Ranking # 366 # 646 # 756 # 820 # 1028
Seq. Equity Growth 4.77 % 5.56 % 5.62 % 6.81 % 5.14 %
Seq. Long Term Debt Growth -40 % -37.5 % 0 % 0 % 0 %


Long Term Debt to Equity for Trailing Twelve Months Period Comment for 12 Months ending at Dec 31 2023
On the trailing twelve months basis Due to long-term debt repayement of -40% United Therapeutics decreased Long Term Debt to Equity for Trailing Twelve Months Period in the IV. Quarter to 0.11, below company's average Long Term Debt to Equity for Trailing Twelve Months Period.
Long Term Debt to Equity for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies in Major Pharmaceutical Preparations industry 9 other companies have achieved lower Long Term Debt to Equity for Trailing Twelve Months Period than United Therapeutics. While total ranking remained unchanged compare to previous quarter at no. .

What is Long Term Debt to Equity Ratio?
What is UTHR selling?
Long Term Debt to Equity UTHR in the most recent quarter
Long Term Debt to Equity for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 10
Sector # 28
S&P 500 # 216


Long Term Debt to Equity for Trailing Twelve Months Period Statistics
High Average Low
0.31 0.18 0.03
(Dec 31 2019)   (Mar 31 2018)




Companies with similar average Long Term Debt to Equity for Trailing Twelve Months Period for 12 months ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Long Term Debt to Equity for Trailing Twelve Months Period
Verrica Pharmaceuticals Inc   0.29 
Zevra Therapeutics Inc   0.29 
Xoma Corporation  0.27 
Uniqure N v   0.27 
Eagle Pharmaceuticals inc   0.26 
Eton Pharmaceuticals Inc   0.26 
Alkermes Plc   0.26 
Centessa Pharmaceuticals Plc  0.24 
Organogenesis Holdings Inc   0.24 
Werewolf Therapeutics Inc   0.23 
Summit Therapeutics Inc   0.23 
Assertio Holdings inc   0.23 
Earth Science Tech Inc   0.23 
Kineta Inc   0.22 
Savara Inc   0.22 
Vera Therapeutics Inc   0.21 
Hcw Biologics Inc   0.20 
Provention Bio Inc   0.19 
Iveric Bio Inc   0.19 
Cue Biopharma Inc   0.18 
Biomarin Pharmaceutical Inc  0.18 
Gossamer Bio Inc   0.17 
Geron Corp  0.16 
Inozyme Pharma Inc   0.16 
Kamada Ltd   0.15 
Elite Pharmaceuticals Inc   0.15 
Adial Pharmaceuticals Inc   0.14 
Roivant Sciences Ltd   0.14 
Opko Health Inc   0.14 
Vaxxinity Inc   0.13 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com